Derlis Gonzalez

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial

Raphael Schiffmann, Özlem Göker-Alpan, Myrl Holida et al. · Journal of Inherited Metabolic Disease · 2019 · 137 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study

Derlis Gonzalez, Hadhami Ben Turkia, Elena Lukina et al. · American Journal of Hematology · 2012 · 87 citations · Full text

Life Sciences, Hematology, Pharmacotherapy +15

Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease

Hadhami Ben Turkia, Derlis Gonzalez, Norman W. Barton et al. · American Journal of Hematology · 2012 · 70 citations · Full text

Medicine, Hematology, Pharmacotherapy +10

Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long‐term data from phase III clinical trials

Derralynn Hughes, Derlis Gonzalez, Elena Lukina et al. · American Journal of Hematology · 2015 · 53 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach

Myrna Candelaria, Derlis Gonzalez, Francisco Javier Fernández Gómez et al. · Cancer Chemotherapy and Pharmacology · 2018 · 37 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13